When Chinese patients with plasma cell disorders encountered the nationwide Omicron outbreak (December 2022): a real-world multicenter and multiregional study

doi:10.1080/16078454.2024.2411741

科研成果详情

题名	When Chinese patients with plasma cell disorders encountered the nationwide Omicron outbreak (December 2022): a real-world multicenter and multiregional study
作者	Jiang, Xincheng 1,2; Han, Xiaoyan 1,2; Jin, Fengyan 3; An, Gang 4; Hou, Jian 5; He, Jingsong 1,2; Wang, Qingming 6; Wu, Wenjun 1,2; Zhao, Yi 1,2; Jiang, Songfu7; Li, Shuchan 1,2; Xu, Zhenshu 8; Zheng, Gaofeng 1,2; Yang, Yang 1,2; Chen, Qingxiao 1,2; He, Donghua 1,2; Li, Yi 1,2; Cai, Zhen 1,2,9
发表日期	2024-12-31
发表期刊	HEMATOLOGY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Plasma cell disorder Omicron COVID-19 China
其他关键词	COVID-19
摘要	ObjectivesThis study aims to assess the impact of the nationwide Omicron outbreak in December 2022 on Chinese patients with plasma cell disorders (PCD), focusing on the clinical characteristics of PCD patients with COVID-19 and the risk factors contributing to adverse clinical courses (severity and hospitalization) and outcomes. MethodsA multicenter retrospective study was performed from December 1, 2022, to January 19, 2023. The study population includes 404 PCD patients, divided into a COVID-19 group (n = 342) and an uninfected group (n = 62). ResultsThe frequency of COVID-19 infection was 84.7% (342/404), and 16.4% (56/342) were severe COVID-19. Among the 277 patients with complete follow-up, 2 deaths (0.7%) were reported, while 231 (83.4%) recovered from COVID-19. Age > 65 (P = 0.02) and prior anti-CD38 monoclonal antibody (mAb) treatment within six months (P = 0.03) were independent risk factors for severe infection. Additionally, previous chimeric antigen receptor T-cell (CAR-T) therapy within six months was correlated with a higher risk of hospitalization (P = 0.04) and prolonged recovery time (P = 0.03). No significant protective effect of vaccination on infection or severe infection was observed (P > 0.05). ConclusionsThe latest Omicron outbreak results in higher rates of severe infection and mortality in PCD patients compared with the general population in China, highlighting the need to protect this vulnerable population during the pandemic. Recent use of anti-CD38 mAb and CAR-T therapy are associated with poorer clinical courses and outcomes of PCD patients with COVID-19.
资助项目	National Natural Science Foundation of China [82270205, 82173267]; Natural Science Foundation of Zhejiang Province [LQ21H160015]
出版者	TAYLOR & FRANCIS LTD
ISSN	1024-5332
EISSN	1607-8454
卷号	29 期号:1
DOI	10.1080/16078454.2024.2411741
页数	9
WOS类目	Hematology
WOS研究方向	Hematology
WOS记录号	WOS:001330471300001
收录类别	SCIE ; PUBMED
URL	查看原文
PubMed ID	39373666
通讯作者地址	[Cai, Zhen]Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China.
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/220600
专题	附属第一医院附属第一医院_血液内科
通讯作者	Cai, Zhen
作者单位	1.Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hematol, Hangzhou, Peoples R China; 2.Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, Hangzhou, Peoples R China; 3.First Hosp Jilin Univ, Dept Hematol, Changchun, Peoples R China; 4.Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China; 5.Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Hematol, Shanghai, Peoples R China; 6.Nanchang Univ, Affiliated Hosp 2, Dept Hematol, Nanchang, Peoples R China; 7.Wenzhou Med Univ, Affiliated Hosp 1, Dept Hematol, Wenzhou, Peoples R China; 8.Fujian Med Univ, Fujian Inst Hematol, Union Hosp, Fuzhou, Peoples R China; 9.Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Jiang, Xincheng,Han, Xiaoyan,Jin, Fengyan,et al. When Chinese patients with plasma cell disorders encountered the nationwide Omicron outbreak (December 2022): a real-world multicenter and multiregional study[J]. HEMATOLOGY,2024,29(1).
APA	Jiang, Xincheng., Han, Xiaoyan., Jin, Fengyan., An, Gang., Hou, Jian., ... & Cai, Zhen. (2024). When Chinese patients with plasma cell disorders encountered the nationwide Omicron outbreak (December 2022): a real-world multicenter and multiregional study. HEMATOLOGY, 29(1).
MLA	Jiang, Xincheng,et al."When Chinese patients with plasma cell disorders encountered the nationwide Omicron outbreak (December 2022): a real-world multicenter and multiregional study".HEMATOLOGY 29.1(2024).